Foghorn Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 116
- Market Cap
- $439.8M
- Introduction
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulator...
Targeted Protein Degradation Industry Forecast to Reach
The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Oncolytics Biotech Inc. advances pelareorep therapy, showing significant survival benefits in breast cancer patients. Other biotech companies like Nurix, Incyte, Regeneron, and Foghorn also report promising developments in cancer treatments.
SEC Form SC 13G filed by Foghorn Therapeutics Inc.
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn report beneficial ownership of 2,935,295 shares (5.31%) of Foghorn Therapeutics Inc. common stock, with shared voting and dispositive power.
© Copyright 2024. All Rights Reserved by MedPath